SCHEMBL4049332

SCHEMBL4049332

[c]1nc(-c2cc3ccccc3cn2)c[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.45
CYP1A2 P05177 2/20 0.44
KDM4E B2RXH2 1/20 0.44
BTK Q06187 1/20 0.44
RAB9A P51151 2/20 0.42
TDP1 Q9NUW8 1/20 0.41
CYP2A6 P11509 1/20 0.40
PDPK1 O15530 1/20 0.40
MIF P14174 1/20 0.38
NPY5R Q15761 1/20 0.38
HTR3A P46098 1/20 0.35
GRM4 Q14833 1/20 0.35
PLAU P00749 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5470573 0.79 NPC1 (0.63) NPC1CYP1A2KDM4EBTKRAB9A
SCHEMBL4050038 0.74 CYP1A2 (0.47) NPC1CYP1A2KDM4ERAB9A
SCHEMBL4049400 0.72 PDGFRB (0.49) CYP1A2CYP2A6
SCHEMBL4049452 0.71 ASIC3 (0.47) NPC1CYP1A2RAB9AMIFL3MBTL1
SCHEMBL972227 0.71 KDM4E (0.56) NPC1CYP1A2KDM4EBTKRAB9A
SCHEMBL4046197 0.70 RAB9A (0.45) NPC1CYP1A2KDM4ERAB9ATDP1
SCHEMBL6161532 0.70 NPC1 (0.47) NPC1CYP1A2KDM4EBTKRAB9A
SCHEMBL17625954 0.70 NPC1 (0.46) NPC1CYP1A2KDM4EBTKRAB9A
SCHEMBL4051363 0.70 ASIC3 (0.39) CYP1A2PLAU
SCHEMBL28271036 0.69 NPC1 (0.74) NPC1CYP1A2KDM4EBTKRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589096-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-15 US disclosed
EP-1566384-B1 NOVEL AZOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2009-06-17 EP disclosed
US-20080188507-A1 Novel azole derivatives MSD K.K. (JP) 2008-08-07 US disclosed
US-7365079-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-29 US disclosed
US-20060111380-A1 Novel azole derivatives MSD K.K. (JP) 2006-05-25 US disclosed
EP-1566384-A1 NOVEL AZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188507-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R NPC1 4195/4885CYP1A2 333/4885KDM4E 2034/4885
US-20060111380-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R NPC1 4203/4885CYP1A2 335/4885KDM4E 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.